TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Consolidated Financial Statements and Management's Discussion and Analysis report for the year ended December 31, 2023, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com.
"As VitalHub closes another quarter, it's with a great sense of achievement that we reflect on the strides we've made. Our Q4 2023 revenue reached $13,603,419, marking a 20% increase over the same period last year. This growth underscores the successful execution of our strategy and the unwavering dedication of our team. Q4 gross profit as a percentage of revenue improved to 83%, up from 82% in the prior year quarter, demonstrating our ability to enhance margins while expanding our service offerings. This is a reflection of our growing recurring revenue base to 83% of revenue compared to 77% in the prior year quarter. We achieved Annual Recurring Revenue (ARR) of $44,573,739, a testament to our robust business model and the trust our clients place in our solutions. ARR increased 23% over the same period last year. The bulk of this ARR growth, $6,387,730 or 18%, was organic, $1,100,000 or 3% was from acquisitions, and $938,859 or 3% was from currency fluctuations. Significantly, our EBITDA for Q4 surged by 536% to $2,992,273, and our adjusted EBITDA (Non-IFRS measure) saw a 62% increase to $3,985,553. These figures are a clear indication of our operational efficiency and the scalability of our platform. Notably, our net income before taxes stood at $1,984,246, illustrating a substantial improvement from the previous year and underscoring our fiscal health and the effectiveness of our growth strategies," said Dan Matlow, Chief Executive Officer of VitalHub.
"Looking at the annual highlights, our revenue for 2023 was $52,508,298, a 31% increase from the previous year, with gross profit remaining robust at 82%. Our EBITDA for the year almost doubled to $9,887,842, and we closed with an adjusted EBITDA of $13,291,526, reinforcing our operational strength and market position. Our cash position improved, with $33,480,018 on hand, thanks to our disciplined approach to cash management and operational excellence. This solid financial foundation empowers us to continue our investment in innovation, pursue strategic acquisitions, and further our mission to transform healthcare technology. As we look to the future, our focus remains on driving sustainable growth, expanding our market reach, and delivering exceptional value to our clients and shareholders. With a clear strategy and a dedicated team, I am confident in our ability to navigate the opportunities and challenges ahead. I want to extend my heartfelt thanks to our employees for their dedication and hard work, our customers for their trust and partnership, and our shareholders for their continued support. Together, we are setting new standards in healthcare technology, and I am excited for what the future holds for VitalHub."
VitalHub Corp’s quarterly investor conference call will take place on Friday, March 22nd, 2024, at 9:00AM EST.
To register for the call, please visit:
https://us02web.zoom.us/webinar/register/WN_BERtvZQxTRuBDjh3Q_PO2A#/registration
Fourth Quarter 2023 Highlights
Annual 2023 Highlights
(1) | The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions of the renewable software license fees and maintenance services. | |
(2) | Non-IFRS measure. |
SELECTED FINANCIAL INFORMATION | ||||||||||
Three months ended | Year ended | |||||||||
December 31, 2023 | % Revenue | December 31, 2022 | % Revenue | Change | December 31, 2023 | % Revenue | December 31, 2022 | % Revenue | Change | |
$ | $ | % | $ | $ | % | |||||
Revenue | 13,603,419 | 100% | 11,289,606 | 100% | 20% | 52,508,298 | 100% | 39,970,814 | 100% | 31% |
Cost of sales | 2,364,543 | 17% | 1,999,560 | 18% | (18%) | 9,697,998 | 18% | 7,031,819 | 18% | (38%) |
Gross profit | 11,238,876 | 83% | 9,290,046 | 82% | 21% | 42,810,300 | 82% | 32,938,995 | 82% | 30% |
Operating expenses | ||||||||||
General and administrative | 2,911,708 | 21% | 2,390,847 | 21% | (22%) | 11,765,148 | 22% | 8,556,468 | 21% | (38%) |
Sales and marketing | 1,394,948 | 10% | 1,126,839 | 10% | (24%) | 5,883,267 | 11% | 4,275,151 | 11% | (38%) |
Research and development | 3,188,172 | 23% | 3,223,157 | 29% | 1% | 12,169,285 | 23% | 10,431,212 | 26% | (17%) |
Depreciation of property and equipment | 76,496 | 1% | 76,422 | 1% | (0%) | 318,866 | 1% | 250,287 | 1% | (27%) |
Depreciation of right-of-use assets | 101,115 | 1% | 163,222 | 1% | 38% | 399,715 | 1% | 342,863 | 1% | (17%) |
Stock based compensation | 220,494 | 2% | 267,584 | 2% | 18% | 1,058,919 | 2% | 1,140,387 | 3% | 7% |
Deferred share-based compensation | - | 0% | - | 0% | 0% | 97,560 | 0% | - | 0% | (100%) |
Foreign currency (gain) loss | (241,505) | (2%) | 93,826 | 1% | 357% | (296,824) | (1%) | 150,399 | 0% | 297% |
Other income and expenses | ||||||||||
Amortization of intangible assets | 1,067,885 | 8% | 952,787 | 8% | (12%) | 4,259,113 | 8% | 3,279,803 | 8% | (30%) |
Business acquisition, restructuring and integration costs | 306,741 | 2% | 1,022,171 | 9% | 70% | 1,534,835 | 3% | 2,438,904 | 6% | 37% |
Loss on change in fair value of contingent consideration | 466,045 | 3% | 695,402 | 6% | 33% | 712,370 | 1% | 695,402 | 2% | (2%) |
Interest expense and accretion (net of interest income) | (252,294) | (2%) | 10,288 | 0% | (2552%) | (489,566) | (1%) | 40,914 | 0% | 1297% |
Interest expense from lease liabilities | 14,825 | 0% | (76,163) | (1%) | 119% | 71,981 | 0% | 29,431 | 0% | (145%) |
(Gain) loss on disposal of property and equipment | 0 | 0% | 0 | 0% | 0% | (2,102) | (0%) | 1,057 | 0% | 299% |
Current and deferred income taxes | 1,045,457 | 8% | (318,005) | (3%) | 429% | 778,248 | 1% | 92,081 | 0% | (745%) |
Net income | 938,789 | 7% | (338,331) | (3%) | 377% | 4,549,485 | 9% | 1,214,636 | 3% | 275% |
EBITDA (Non-IFRS measure) | 2,992,273 | 22% | 470,220 | 4% | 536% | 9,887,842 | 19% | 5,250,015 | 13% | 88% |
Adjusted EBITDA (Non-IFRS measure) | 3,985,553 | 29% | 2,455,377 | 22% | 62% | 13,291,526 | 25% | 9,524,708 | 24% | 40% |
Annual recurring revenue (Non-IFRS measure) | 44,573,739 | 36,145,150 | 23% | 44,573,739 | 36,145,150 | 23% | ||||
Term licences, maintenance and support revenue | 11,302,366 | 83% | 8,736,265 | 77% | 29% | 42,332,253 | 81% | 29,359,361 | 73% | 44% |
As at | ||||||||||
December 31, 2023 | December 31, 2022 | |||||||||
$ | $ | |||||||||
Deferred revenue | 21,049,975 | 15,495,461 | ||||||||
Cash balance | 33,480,018 | 17,452,210 |
ABOUT VITALHUB
Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.
VitalHub Corp. (the “Company” or “VitalHub”) provides technology to Health and Human Services providers including Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination & Optimization, and Patient Flow & Operational Visibility solutions.
The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive merger and acquisition (“M&A”) plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.
VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 400 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol “VHIBF”.
CAUTIONARY STATEMENT
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$10.81 |
Daily Change: | -0.12 -1.10 |
Daily Volume: | 112,898 |
Market Cap: | C$549.690M |
November 13, 2024 October 30, 2024 August 08, 2024 July 30, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB